Top

Published in:

01-11-2015 | Original Research

Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population

Authors: Aaron S. Kesselheim, MD, JD, MPH, Jessica M. Franklin, PhD, Seoyoung C. Kim, MD, ScD, MSCE, John D. Seeger, PharmD, DrPH, Daniel H. Solomon, MD, MPH

Published in: Journal of General Internal Medicine | Issue 11/2015

Abstract

Background

A brand-name version of colchicine (Colcrys) was introduced after its manufacturer conducted a clinical trial in acute gout patients, leading to higher prices for this drug.

Objective

We analyzed the impact of the new single-source colchicine product on prescribing and patient health spending as well as incidence rates of potentially dangerous concomitant use of clarithromycin and cyclosporine after formal FDA approval.

Design/Participants

We conducted a retrospective cohort study of UnitedHealth-affiliated enrollees newly diagnosed with gout or FMF.

Main Measures

Among gout and FMF patients separately, we assessed linear trends in colchicine prescriptions, prescription drug costs, and total health care costs from 2009 to September 2010 (market exclusivity announced) compared to January 2011 (market exclusivity enforced) through 2012. Next, we estimated trends in co-prescription within 15 days of clarithromycin, azithromycin (indicated on the Colcrys label for use in place of clarithromycin), and cyclosporine.

Key Results

Among gout patients, before Colcrys’ market exclusivity, the odds of receiving colchicine within 30 days of gout diagnosis increased 1.4 %/month (OR: 1.014, 95 % CI: 1.011–1.018). Following FDA action, the odds decreased by 0.5 %/month (OR: 0.995, 95 % CI: 0.992–0.999) (p < 0.001). Similarly, among FMF patients, odds of initiating colchicine changed from an increase of 2.8 %/month to a decrease by 7.6 %/month (p = 0.01). Patients receiving colchicine experienced increases in average monthly prescription drug costs ($418 vs. $651, p < 0.001) and health care costs ($3,406 vs. $3,534, p < 0.001). Incidence rates of colchicine/clarithromycin co-prescription before and after FDA action did not change, while co-prescription of colchicine/cyclosporine increased after introduction of Colcrys [−0.75 monthly change in patients (95 % CI: -1.07, -0.43) vs. 0.13 (95 % CI: -0.16, 0.42), p < 0.001].

Conclusions

The FDA’s actions were associated with a reduction in colchicine initiation and an increase in patient spending. By contrast, we did not observe any association with improvements in avoidance of potentially dangerous co-prescriptions.

Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton: Princeton Univ Press; 2010.

Food and Drug Administration. Unapproved drugs initiative. Jan 5 2011. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ucm118990.htm.

Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four–hour outcome of the first multicenter, randomized, double-blind, placebo- controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8.CrossRefPubMed

Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I. EULAR evidence based recommendations for gout, part II: management. Ann Rheum Dis. 2006;65(10):1312–24.PubMedCentralCrossRefPubMed

Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med. 1987;17(3):301–4.CrossRef

Kesselheim AS, Solomon DH. Author Reply re: Incentives for drug development—the curious case of colchicine. N Engl J Med. 2010;363(15):1484–5.CrossRef

Rockoff JD. An old gout drug gets new life and a new price, riling patients. Wall St. J. 12 Apr 2010.

Center for Drug Evaluation and Research. Application number 22–352: medical review. 24 Nov 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022352s000_MedR.pdf.

Kesselheim AS, Solomon DH. Incentives for drug development—the curious case of colchicine. N Engl J Med. 2010;362(22):2045–7.CrossRefPubMed

10.

Woodcock J, Okada S. Letter to the Editor re: Incentives for drug development—the curious case of colchicine. N Engl J Med. 2010;363(15):1484.CrossRefPubMed

11.

Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–37.CrossRefPubMed

12.

AR Scientific Inc. Highlights of prescribing information: colchicine (Colcrys). Jul 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022352lbl.pdf.

13.

Food and Drug Administration. FDA orders halt to marketing of unapproved single-ingredient oral colchicine. 30 Sept 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm227796.htm.

14.

Guglielmo BJ. The colchicine debacle. JAMA Intern Med. 2013;173(3):184–5.CrossRefPubMed

15.

Eng PM, Johannes CB, Chiang CC, West WA, Seeger JD, Walker AM. Survey of disability, medication use, and medication satisfaction among members with rheumatoid arthritis of a large health care plan database. Pharmacoepidemiol Drug Saf. 2005;14:S1–218.

16.

UnitedHealthcare. Your 2012 prescription drug list: quick-reference guide. Sept 2011.

17.

UnitedHealthcare. 2011 three-tier prescription drug list: consumer reference guide. Sept 2010.

18.

Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50(4):285–95.PubMedCentralCrossRefPubMed

19.

Food and Drug Administration. FDA approves colchicine for acute gout, Mediterranean fever. 30 Jul 2009. Available at: www.fda.gov/newsevents/newsroom/pressannouncements/ucm174620.htm

20.

Aetna. 2013 Aetna comprehensive formulary drug list (base). September 2013. Available at: http://www.aetnamedicare.com/documents/individual/2013/formularies/2013_medicare_cvs_essentials_preferred_drug_list.pdf.

21.

Cigna Healthcare. Drug list search results. Available at: https://my.cigna.com/teamsite/cgi-bin/customer_care/member/drug_list/DrugList.cgi?search_by=name&LeanIndicator=&referer=&Pid=#Cdrugs.

22.

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.CrossRefPubMed

23.

Meyer H. Is FDA approval for safety…or price gouging? LA Times. 18 Jan 2010.

24.

Grody WW, Getzug T. Colchicine’s other indication—effect of FDA action. N Engl J Med. 2010;363(23):2267–8.CrossRefPubMed

25.

Ullman K. Colcrys approval triggers questions. The Rheumatologist. May 2010. Available at: http://www.the-rheumatologist.org/details/article/865591/Colcrys_Approval_Triggers_Questions.html.

26.

Rosenthal E. The soaring cost of a single breath. NY Times. 12 Oct 2013.

27.

Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systematic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008;2, CD005521.PubMed

28.

Jagger J. Survey report: comparative colchicine brand response in FMF patients. Eurordis. 10 Apr 2011. Available at: http://download.eurordis.org/documents/pdf/FMFSurveyallcases_latest.pdf.

29.

National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States. 15 Nov 2012. Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/#11.

30.

Stamp LK, Chapman PT. Gout and organ transplantation. Curr Rheumatol Rep. 2012;14(2):165–72.CrossRefPubMed

31.

Howard DH. Drug companies’ patient-assistance programs–helping patients or profits? N Engl J Med. 2014;371(2):97–9.CrossRefPubMed

32.

Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK, Cheung BM, Yuen KY. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005;41(3):291–300.CrossRefPubMed

33.

Khanna D, Fitzgeralf JD, Khanna PP, Bae S, Signh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.CrossRef

Title: Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population
Authors: Aaron S. Kesselheim, MD, JD, MPH
Jessica M. Franklin, PhD
Seoyoung C. Kim, MD, ScD, MSCE
John D. Seeger, PharmD, DrPH
Daniel H. Solomon, MD, MPH
Publication date: 01-11-2015
Publisher: Springer US
Published in: Journal of General Internal Medicine / Issue 11/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-015-3285-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Design/Participants

Main Measures

Key Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2015

Inpatient Hospital Charge Variability of U.S. Hospitals

The ACA’s 65th Birthday Challenge: Moving from Medicaid to Medicare

Impact of an Intervention to Improve Weekend Hospital Care at an Academic Medical Center: An Observational Study

CMS Reimbursement Reform

Capsule Commentary on Perez, Doig-Acuna, and Starrels, “Not Unless It’s a Life or Death Thing”: A Qualitative Study of the Health Care Experiences of Adults Who Stutter

Adult Patients’ Perspectives on the Benefits and Harms of Overused Screening Tests: a Qualitative Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials